Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) logo

Product menu

NA

Real-world evidence for Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol) in patients with COPD

Data from 2 separate real-world comparative effectiveness studies in patients with COPD stepping up from dual therapy

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).1

The real-world evidence for Trelegy Ellipta is building

  • Picture of an older man
    There is now UK head-to-head real-world data for Trelegy Ellipta versus Trimbow (BEGF) pMDI2

    Find out more
    An independent real world study
  • Image of older lady with glasses
    Trelegy Ellipta also has head-to-head real-world data versus another triple therapy – Trixeo (BUD/GLY/FOR)3

    Explore the study
    Real‑world study in patients with COPD
Picture of an older man with glasses

Evidence that makes a difference to patients and practice

Trelegy Ellipta: A triple therapy shown to improve quality of life and patient outcomes while reducing healthcare burden3,4

Real world evidence for Trelegy Ellipta vs Trixeo (BUD/GLY/FOR)

In a retrospective real-world evidence cohort comparative effectiveness study (CES) of patients with COPD previously treated with dual therapy (LAMA/LABA or ICS/LABA) in the USA. Results are reflective of the population studied and may not be generalisable. n=10,093 Trelegy Ellipta; n=3,926 BUD/GLY/FOR

Illustration of a Trelegy Ellipta outline with a pair of lungs inside.

Trelegy Ellipta has shown a significant reduction in moderate–severe exacerbations vs BUD/GLY/FOR in patients who need to step-up from dual therapy (LAMA/LABA or ICS/ LABA)3

Watch data summary
Illustration of an exhale of breath with a -18% figure

Trelegy Ellipta significantly reduced the annual rate of moderate-severe exacerbations by 18% vs BUD/GLY/FOR3

RR: 0.82 (95% CI: 0.77, 0.88); p<0.001. Absolute difference: -0.18 exacerbations PPY. Annualised rate of moderate-severe COPD exacerbations PPY:Trelegy Ellipta: 0.8; BUD/ GLY/FOR: 0.98'

See study design
Illustration 4 blue hearts and one white heart and an 18%

Trelegy Ellipta significantly lowered the risk of all-cause mortality by 18% vs BUD/GLY/ FOR at 12 months3

HR at 12 months 0.82 (95% CI: 0.68 0.99); p=0.040. KM- estimated risk at 12 months 4.9% vs 6.0% (absolute difference -1.1%).

All-cause mortality was an exploratory endpoint. While exploratory findings may provide valuable insights, they are not typically designed to demonstrate definitive clinical efficacy.

Explore Ellipta device

Results are reflective of the population studied and may not be generalisable.

Primary outcome: Annualised rate of moderate-severe COPD exacerbations between patients treated with FF/UMEC/VI and BUD/ GLY/FOR who used dual therapy as their latest treatment before stepping up. All-Cause Mortality was an exploratory endpoint. While exploratory findings may provide valuable insights, they are not typically designed to demonstrate definitive clinical efficacy.

Disease area

About Trelegy Ellipta

Device

Ellipta Inhaler

Management

COPD & Guidelines

Resources

Support

VIDEO: Overview of real-world Trelegy Ellipta COPD insights from the comparative effectiveness study with Trixeo

Professor Wisia Wedzicha of Imperial College London explores the real-world evidence from the Comparative Effectiveness Study.

GSK resources for COPD management

Image showing Inhale, a hub to support COPD consultations

COPD RESOURCES

Inhale hub for patient support

Information to support COPD consultations with your patients

View resource

Illustration of lungs and paperwork symbolising guidelines for COPD, with the letters GSK in the pages

GUIDELINES

GSK Summary

Overview of where triple therapy fits into NICE and GOLD guidelines

View resource

Icon of a shopping trolley

PATIENT SUPPORT

Online ordering

Explore our online catalogue of resources to support patients with COPD who have been prescribed Trelegy Ellipta

View resource

Abbreviations:

BEGF: beclometasone/glycopyrronium/formoterol; BUD/GLY/FOR: budesonide/glycopyrronium/formoterol; CES: comparative effectiveness study; CI: confidence interval; HR: hazard ratio; ICS: inhaled corticosteroid; KM: Kaplan meier; LABA: long-acting beta agonist; LAMA: long-acting muscarinic antagonist; pMDI: pressured meter dose inhaler; RCTs: randomised controlled trials; RR: risk ratio

References:

  1. Trelegy Ellipta Summary of Product Characteristics.
  2. Cherian M et al. Int J COPD 2026;21:585037.
  3. Wedzicha JA et al. Adv Ther 2025; 42(9):4432-4446.
  4. Lipson DA et al. Am J Respir Crit Care Med 2017;196(4):438-446.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.

September 2026 | PM-GB-FVU-WCNT-260003 (V1.0)